New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
07:46 EDTIPXL, AVNRAvanir likely win patent case against Impax, says Jefferies
After reviewing court transcripts, Jefferies believes Avanir (AVNR) is likely to win its Nuedexta patent trial against Impax (IPXL). The firm says that while the stock is may rally on the patent win, it sees limited upside and keeps a Hold rating on Avanir. Jefferies notes that its $4 price target already assumes full credit for the Nuedexta patent.
News For AVNR;IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
07:12 EDTIPXLImpax to release guidance when Tower Holdings, Lineage acquisitions completed
Subscribe for More Information
07:12 EDTIPXLImpax reports Q4 adjusted EPS 16c, consensus 12c
Reports Q4 revenue $131.2M, consensus $125.47M. Reports Q4 Global Pharmaceuticals revenue $117.9M. The increase is due to higher sales of several key generic products as well as the impact of customer credits that were recorded in the prior year period of $19.2 million as a result of customer credits relating to certain pricing activities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use